SCHEMBL10150152

SCHEMBL10150152

CC1CCc2c(nc(-c3ccccc3F)nc2N2CCN(C)CC2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
GLA P06280 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.43
HIF1A Q16665 1/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
CYP1A2 P05177 3/20 0.42
CYP3A4 P08684 3/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP2D6 P10635 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPK1 P28482 2/20 0.41
HRH1 P35367 2/20 0.41
HRH4 Q9H3N8 2/20 0.41
KMT2A Q03164 2/20 0.41
HRH2 P25021 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150143 0.91 HIF1A (0.52) TSHRGLANPSR1MAPTLMNA
SCHEMBL10150366 0.91 TSHR (0.47) TSHRGLANPSR1MAPTLMNA
SCHEMBL10150146 0.88 TSHR (0.47) TSHRGLANPSR1MAPTLMNA
SCHEMBL8299287 0.87 MEN1 (0.57) TSHRGLANPSR1MAPTLMNA
SCHEMBL10150326 0.78 MEN1 (0.57) TSHRMAPTCYP1A2CYP3A4ALDH1A1
SCHEMBL10150299 0.77 ALDH1A1 (0.53) TSHRNPSR1MAPTLMNAHIF1A
SCHEMBL8297579 0.77 ALDH1A1 (0.53) TSHRNPSR1MAPTLMNAHIF1A
SCHEMBL10150306 0.77 SMAD3 (0.53) TSHRGLANPSR1MAPTLMNA
SCHEMBL8297570 0.77 SMAD3 (0.53) TSHRGLANPSR1MAPTLMNA
SCHEMBL8299276 0.76 SMAD3 (0.52) TSHRNPSR1MAPTLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 TSHR 4248/4885GLA 2879/4885NPSR1 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.